To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

November 01, 2019___

Today's Rundown

Featured Story

Amgen pays $2.7B to enlist BeiGene as Chinese R&D partner

Amgen is paying $2.7 billion for a 20.5% stake in BeiGene. The investment will put BeiGene at the heart of Amgen’s efforts to develop oncology drugs for the Chinese market. 

Top Stories

Novo drops oral GLP-1 analog to focus on next-gen Rybelsus

Novo Nordisk has stopped development of its next-generation oral GLP-1 analog OG2023SC. The Danish drugmaker took the action after making progress with an enhanced version of its existing oral semaglutide formulation.

AstraZeneca spinout Entasis nabs Shire exec as CMO

After getting off a $75 million IPO last year, AstraZeneca’s antibiotics spinout Entasis has hired a former Shire executive to lead its R&D programs.

[Sponsored] RenMab™ Mouse: a leading platform for fully human antibody generation

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts, authentic position within the chromosome.

Foresite unveils incubator focused on 'nexus of data science and healthcare'

Foresite Capital launched a new incubator working on companies at the intersection of data science and healthcare, led by its managing director and former Verily and Grail exec, Vik Bajaj, Ph.D. The firm started the incubator, dubbed Foresite Labs, to help usher in a transformation in healthcare.

EuroBiotech Report—Roche-Dicerna, GSK in TB, Sanifit data, filgotinib and Novartis

In this week's EuroBiotech Report, Roche inks $200 million RNAi deal, GSK's tuberculosis vaccine shows durability and Sanifit clears phase 2b.

Chutes & Ladders—Roche taps Sause to head North American ops

Roche Diagnostics nabs Sause to head North American ops; Hung founds new biotech Nuvation; Sonde Health taps Liu as CEO.

FiercePharmaAsia—Takeda's rare disease decline; Astellas-Pandion diabetes deal; I-Mab's Nasdaq IPO

Sales from Takeda's rare disease business dropped on hemophilia competition and Natpara's recall. Astellas inked a Type 1 diabetes collab with Pandion Therapeutics for up to $795 million. Shanghai biotech I-Mab chose Nasdaq for its planned $100 million IPO. And more.

Resources

[Whitepaper] The Impact of Step-Therapy Policies on Patients

Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system.

[Whitepaper] Q2 2019 Biopharma licensing report

18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights.

[Whitepaper] Synthesizing Success: Six Principles For Getting Pharmaceutical Development Right From The Start

Is your API development on track?

[Infographic] Implement the Patient Voice to Build an Effective Engagement App

Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app.

[eBook] Customer Experience: Shaping Digital Healthcare

Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve

[Whitepaper] How to succeed by failing faster

This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy.

[Article] 8 Compelling Reasons Why Businesses Need To Be In The Cloud Now!

Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business.

[Whitepaper] Implementing On-Dose Authentication Technologies for Solid Dose Drug Products

Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions.

[Whitepaper] Cortellis Q2 2019 M&A report

Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends.

[Whitepaper] Best Practices for Incorporating Real World Imaging Data into RWE Programs

The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™

[Whitepaper] Synthesizing Success: Six Principles for Getting Pharmaceutical Development Right from the Start

Is your API development on track?

[Whitepaper] Innovative Funding Models for Treatment of Cancer and Other High-Cost Chronic Noncommunicable Diseases

A global landscape study of funding trends and innovations.

[Case Study] Clinical Supply Management

Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study.

[Video] Demand Led Services and Clinical Supply Efficiency

Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels.

[eBook] Strategies for Efficient Clinical Supply Management and Forecasting

Download the eBook to explore a proactive approach for clinical supply management.

Events